SHANGHAI, Aug. 25, 2021 /PRNewswire/-- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet
technology company offering healthcare professionals the online
healthcare information, professional training and educational
services platform and patients the patient management platform,
today announced its subsidiary Shanghai Zhongxin Medical
Technology Co., Ltd. ("Zhongxin") provides patient follow-up
management services for ovarian cancer patients from Zeyoulexiang
Patient Assistance Project (the "Project"), helping ovarian cancer
patients improve treatment outcomes and eventually increase
survival rate.
The Project, managed by Bethune Charitable Foundation, provides assistance to female patients in
mainland China who meet the
standards to take Niraparib, an anti-cancer medication. Through the
all-in-one patient management system ("All-in-One System")
developed by the Company, patients can record, track and view
various indications of their bodies and disease during the
medication and receive early warnings of potential disease
progression to manage adverse reactions and psychological problems
during medication and improve their adherence to treatment and
treatment safety. In addition, the digital follow-up function
embedded in the All-in-One System allows patient management
specialists and physicians to provide one-on-one medication
guidance and lifestyle advice for patients to ensure correct drugs
usage and response to adverse reactions, improving the treatment
experience.
The Project consists of a service network of more than 350
hospitals, 40 pharmacies, and 1,000 physicians, supported by the
All-in-One System operated by Zhongxin, and is jointly supported
and assisted by Cancer Hospital Chinese Academy of Medical
Sciences, Beijing Obstetrics Gynecology Hospital, Peking Union
Medical College Hospital, Beijing Cancer Hospital, Zhongshan
Hospital of Fudan University, and Red House Hospital. As of
July 2021, more than 5,000 ovarian
cancer patients had received drug assistance and patient management
services through the Project.
According to GlobalData, the ovarian cancer market was valued at
$1.8 billion in 2018 across the seven
major markets, including the USA,
France, Germany, Italy, Spain,
UK and Japan, and it is expected
to grow to $6.7 billion in the next
ten years with a compound annual growth rate of 14.4%. In
China, there were over 50,000
new ovarian cancer cases and more than 30,000 deaths in 2018.
Zhongchao actively expands to the ovarian cancer market, hoping to
assist the treatment of ovarian cancer patients with its All-in-One
System and grow its patient management business within the
high-demand ovarian cancer field.
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is
a platform-based internet technology company. It
provides online healthcare information, professional training and
educational services to healthcare professionals under its "MDMOOC"
platform (www.mdmooc.org) and to the public under its "Sunshine
Health Forums" platform (www.ygjkclass.com) in China. Through its subsidiaries, the Company
also operates a platform offering patient management services. More
information about the Company can be found at its investor
relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the
Company's future business development; product and service demand
and acceptance; changes in technology; economic conditions; the
growth of the professional training and educational services market
in China and the other
international markets the Company plans to serve; reputation and
brand; the impact of competition and pricing; government
regulations; fluctuations in general economic and business
conditions in China and the
international markets the Company plans to serve and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC, the length
and severity of the recent coronavirus outbreak, including its
impacts across our business and operations. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
SEC, which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward–looking
statements to reflect events or circumstances that arise after the
date hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry
Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-expands-patient-management-business-to-ovarian-cancer-market-301362239.html
SOURCE Zhongchao Inc.
